

3rd Human Challenge Trials in Vaccine Development

February 6-7, 2020 - Oxford, United Kingdom

Biosketch



Paul Kaye, PhD, FRCPATH, FMedSci.

Professor of Immunology

Hull York Medical School, University of York

Heslington

York YO32 9FZ

United Kingdom

Tel: +1904 328840

e-mail: paul.kaye@york.ac.uk

Paul Kaye is Professor of Immunology at the Hull York Medical School, University of York. He trained in zoology (BSc) and immunology (PhD) and has worked for over 30 years on the immunology and immunopathology of the neglected tropical disease leishmaniasis. In addition to his work in leishmaniasis, he is internationally recognized for his research on macrophages and dendritic cells, contributing to a fundamental understanding of their biology in health and disease, and for his work on lymphoid tissue remodeling and granulomatous inflammation during chronic infection. Paul is a Wellcome Trust Senior Investigator and an elected Fellow of the UK Academy of Medical Sciences. He was awarded FRCPATH in 2004. He has extensive links with leishmaniasis-endemic countries and is currently leading two Phase II therapeutic vaccine trials in Sudan, developing a digital pathology network to enhance data sharing and establishing a controlled human infection model of sand fly transmitted cutaneous leishmaniasis. Paul has published over 120 articles including *Nature Medicine*, *Immunity*, *J. Clin. Invest.*, and *PNAS*, and has received funding as principal investigator or co-investigator of >£35M. Paul is currently Chair of the MRC Infections and Immunity Board and a member of MRC Strategy Board.



IABS - Rue de la Vallée, 3 - 1204 Geneva - Switzerland
Tel : +41 22 301 10 36 - www.iabs.org - iabs@iabs.org